Canada funds the first phase of national pharmacare, diabetes medicines and contraception, one bilateral agreement at a time — as of 2026-09-12 Health Canada records agreements signed with 4 of 13 provinces and territories

What is happening?

On 2024-10-10 the Pharmacare Act received royal assent. The statute sets out four principles for prescription drug coverage — accessibility, affordability, appropriate use and universal coverage — and places on the federal Minister of Health a duty to work toward them with the provinces, the territories and Indigenous peoples.

What the Act delivers today is its first phase and only its first phase: bilateral funding agreements under which a province or territory supplies diabetes medicines and devices, and contraception, at no cost or at minimal cost to the resident.

Four jurisdictions have signed. Manitoba signed on 2025-02-27 for more than 219 million Canadian dollars over four years, with coverage beginning around June 2025. British Columbia signed on 2025-03-06 for more than 670 million Canadian dollars over four years, with coverage beginning in March 2026; the federal announcement put the reach there at about 550,000 people with diabetes and more than 1.3 million people for contraception. Prince Edward Island signed on 2025-03-07 and Yukon on 2025-03-20.

As of 2026-09-12 the Health Canada page that records the current state lists funding agreements with 4 provinces and territories. Canada has ten provinces and three territories.

The projected money is falling. Two sources opened here report that the spring 2026 federal fiscal update projects bilateral health funding dropping from 4.3 billion Canadian dollars in 2025-26 to 3.1 billion in 2027-28, with no amount set aside for new pharmacare agreements. In July 2025 an independent policy research institute and a trade publication each recorded the federal amounts available to three provinces that had not signed — about 2.5 billion Canadian dollars over four years for Ontario, 171 million for Nova Scotia and 136 million for New Brunswick.

The nine without an agreement are not one group. One opened trade publication reports that the governments of Alberta and Quebec have stated that health care is a provincial responsibility and have declined to take part, and that Ontario is waiting to see the details. For the remaining six, no source opened here records a position at all.

Whose problem is this?

The order of government that wrote the four principles into statute is not the order of government that administers the coverage, and the statute does not close that distance. Nothing in it reaches a jurisdiction that has not signed.

Where does this problem end?

The boundary here separates a question about delivery from a question about which order of government should be paying for prescription drugs in the first place. Those two are argued in different forums, and an answer to one of them does not settle the other.

What is the state now, and what should it be?

Now

Needs a new measurementthe target state: the Act names universal coverage among its four principles, and no source opened here supplies a date by which the remaining provinces and territories are to be signed, a share of the population the first phase is meant to reach, or any other measurable target the federal government has set for itself. The four principles describe a direction. Nothing opened here turns them into a number with a date attached.

How big is it?

Two counts are available and neither one is the count this question asks for.

The first is residence. At 2026-04-01 the population of Canada was 41,417,056, and the four jurisdictions with a signed agreement — British Columbia 5,646,420, Manitoba 1,503,865, Prince Edward Island 181,715 and Yukon 48,493 — together held 7,380,493. The remainder, 34,036,563 people, live where no bilateral agreement exists.

A count of the people who live where no agreement exists is not a count of the people who lack coverage for these medicines. Provincial drug plans and employer plans already cover part of that population, and no source opened here measures how large that part is.

The second is reach inside one signed jurisdiction. The federal announcement for British Columbia gave about 550,000 people with diabetes and more than 1.3 million people for contraception. Those figures were measured in one province and cannot be carried across to the others, because extending them would distribute a measured value by population share rather than measure it.

So the quantity at issue is bounded above by the 34.0 million residents of jurisdictions without an agreement at 2026-04-01, has no lower bound that any opened source supplies, and has no published figure in between. The population file records that as not derivable rather than choosing a number inside the gap.

Under what conditions does it arise?

1. The statute delegates delivery to a counterparty that can decline. The Act creates a duty for the federal Minister of Health to work with the provinces and territories. It does not create a route that ends in coverage when a province does not come to an agreement, and no opened source describes one.

2. The money and the administration sit with different governments. The federal government holds the funds and the provinces and territories hold the administration of health care, and the statute does not supply a route that ends in coverage without a signature from each jurisdiction. Two provincial governments have placed exactly that division on the record as their reason for staying out.

3. The agreements are term limited and the projection points down. The two agreements whose terms appear in federal news releases each run four years, and one opened trade publication describes the same term for all four. The spring 2026 fiscal update, as reported by two sources opened here, projects the bilateral health funding envelope falling from 4.3 billion Canadian dollars in 2025-26 to 3.1 billion in 2027-28 and carries no allocation for further pharmacare agreements.

4. Nobody publishes the size of the gap. No opened source counts the people in jurisdictions without an agreement who lack coverage for diabetes medicines or contraception. A shortfall that is never counted produces no figure that anyone has to answer for.

What has been tried?

Two directions ran at once and they point opposite ways. Signatures were gathered for one year, and then the projected envelope for the mechanism that requires them began to shrink. Between those two movements, nine jurisdictions stayed where they were.

What was found?

Why is it still unsolved?

Coordination failure — the federal government wrote the principle and holds the money, and every unit that would have to deliver the coverage is a government it cannot direct.

The first part is structural and it was designed in. A bilateral agreement exists only when both sides sign one, so the coverage exists in a province exactly when that province decides it should. The Act obliges the federal Minister of Health to work with the provinces and territories; working with them is not the same instrument as reaching the people inside them. Four signatures arrived in five weeks in early 2025, and none has been recorded since.

The second part is that nothing in the arrangement carries a clock. No source opened here gives a date by which the remaining nine are meant to sign, a share of the population the first phase is meant to reach, or a review point at which the absence of further agreements would have to be explained. The Act declares universal coverage as a principle and leaves the schedule to a negotiation that has no scheduled end.

The third part is that a falling projection is not an announcement. The reported path for bilateral health funding drops between 2025-26 and 2027-28 and carries nothing for new agreements, and no source opened here contains a statement from the federal government either ending the program or renewing it. A program that stops offering and a program that is still negotiating look the same from outside, because neither one produces an event.

The fourth part is that the cost of the gap is unmeasured. Because nobody publishes how many people in the nine jurisdictions actually lack coverage for these medicine classes, there is no figure that grows each year the situation holds. What is counted instead is signatures, and that number has been the same since March 2025.

What observation would mean it is solved?

Candidates — (a) Health Canada records bilateral agreements with all thirteen provinces and territories (b) coverage is in force and claims are being paid in every jurisdiction that has signed, with a start date reached rather than announced (c) a published count of people in Canada without coverage for diabetes medicines and contraception falls.

(a) alone counts paper. A signature is a funding arrangement, not a prescription filled. The gap between signature and start date ran about three months in one of the two jurisdictions where both dates are recorded and about twelve months in the other, with no published schedule governing either, and an agreement can be signed with a formulary narrow enough, or a cost share high enough, that the person at the counter notices nothing.

(b) alone is still about the four. It would confirm that what was signed actually works, which is worth confirming, and it would say nothing about the nine. A mechanism that delivers perfectly to four jurisdictions out of thirteen is not yet a national program, and reading (b) as an answer mistakes execution for reach.

(c) alone is not attributable and not currently measurable. No opened source publishes that count now, so there is no baseline for it to fall from. Even with a baseline, coverage moves for reasons that have nothing to do with this statute — provincial plans change, employment changes, and a federal agreement is one input among several. The three would have to be read together, and (a) has to be read against the start dates that follow it.

What is it connected to?

Fills with researchthe design of existing provincial and territorial drug plans, the mixed public and private model of drug insurance in Canada, the broader architecture of federal transfers for health, the treatment of pharmaceutical pricing by federal regulators, and pharmacare arrangements in comparable countries. Relation type and evidence grade were not confirmed in this round.

What these sources do not say

• Why each jurisdiction without an agreement has not signed. One opened source records a jurisdictional objection for two provincial governments and a reserved position for a third. For the other six, no opened source carries a recorded position of any kind. Treating the nine as one stance would go past what any source here supports.
• Whether the four signed agreements will be renewed. The two whose terms appear in federal news releases run four years, and no opened source carries a statement from the federal government about what follows the term.
• Whether further agreements are intended. No opened source contains a federal statement on that question. The two sources that report the fiscal projection are an independent policy research institute and a trade publication, and the reading each places on that projection is its own rather than a federal position.
• What the spring 2026 fiscal update itself says. The figures of 4.3 billion and 3.1 billion, and the absence of an allocation for new agreements, reach this document through two secondary sources that cite the update. The update is not among the documents opened here.
• How many people in the nine jurisdictions lack coverage for these medicine classes. That subtraction is the number that would say how large the gap actually is, and no opened source performs it. Residence in a jurisdiction without an agreement is not absence of coverage, because provincial plans and employer plans already cover part of that population, and no opened source dated after the Act measures how much.
• How the coverage performs inside the four signed jurisdictions. No opened source gives uptake, claims volume, or out of pocket cost after a start date was reached.
• What the 2019 advisory council reported in detail. The council and its year appear in the record assembled here, and the report page itself is listed without a confirmed URL below, so its figures are not carried into this document.

See the evidence

No primary budget document was read. The Health Canada agreements page, the Health Canada national pharmacare page, the parliamentary bill document and two federal news releases were opened directly, and they carry the count of signed jurisdictions, the signing dates, the agreement values, the medicine classes and the royal assent date, which are the facts the rest of this document leans on most. The national statistical agency release was opened directly and carries the population figures. The spring 2026 fiscal projection reaches this document only through two secondary sources that cite it, and it is graded accordingly. Where the sources overlap they agree: the count of four signed jurisdictions appears on two Health Canada surfaces, and the projected drop from 4.3 billion to 3.1 billion appears in both secondary sources. Where they are silent the silence is left visible rather than filled — no federal statement on renewal, no federal deadline, no position recorded for six of the nine jurisdictions without an agreement, and no count anywhere of the people those nine jurisdictions contain who lack coverage for the medicine classes at issue. Two of the sources listed above carry an adverse characterization of the federal position in their own published wording; that reading belongs to each publisher and is not adopted in this document. This is a Path A output, a research-based definition, so observation_refs is empty and provenance_mode: press-derived.

People affected

Estimated range Not derivable

The reason and what is missing are listed under “What is missing” below